NCT01960829

Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study

A Single-armed, Open-labeled and Single-centered Phase II Trial of Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Peking University Cancer Hospital & Institute · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is a single-armed, open-labeled and single-centered study of everolimus in selective patients with metastatic melanoma for evaluation of the efficacy and safety. The study objective is to evaluate efficacy profile of everolimus. The patients who comply with the inclusion and exclusion criteria will be enrolled. The estimated recruiting duration is 18 months. Everolimus will be given in the dose of 10 mg orally each day at lease 6 months unless disease progression or intolerance. The follow-up is till death(at least 1 year).

Conditions

• Melanoma
• TOR Serine-Threonine Kinases
• Neoplasm Metastasis

Interventions

Type	Name	Description
DRUG	Everolimus

Timeline

• Start date: 2013-09-01
• Primary completion: 2015-05-01
• First posted: 2013-10-11
• Last updated: 2015-05-01

Locations

1 site across 1 country: China